# An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19

> **NCT04412018** · PHASE2 · COMPLETED · sponsor: **Canadian Medical and Surgical Knowledge Translation Research Group** · enrollment: 100 (actual)

## Conditions studied

- COVID-19
- Inflammatory Response

## Interventions

- **DRUG:** Icosapent ethyl

## Key facts

- **NCT ID:** NCT04412018
- **Lead sponsor:** Canadian Medical and Surgical Knowledge Translation Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-04
- **Primary completion:** 2020-11-06
- **Final completion:** 2020-12-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04412018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04412018, "An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04412018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*